Japanese pharma group declares win in billion-dollar royalties dispute
Gilenya is an oral tablet to treat multiple sclerosis (Credit: Shutterstock/Andrey Mihaylov)
Japan’s Mitsubishi Tanabe Pharma Corporation says it has defeated an ICC claim brought by Switzerland’s Novartis over royalties for a treatment for multiple sclerosis – a dispute understood to be worth around US$3 billion.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now